Amber C. King

782 total citations
31 papers, 419 citations indexed

About

Amber C. King is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Hematology. According to data from OpenAlex, Amber C. King has authored 31 papers receiving a total of 419 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 11 papers in Public Health, Environmental and Occupational Health and 11 papers in Hematology. Recurrent topics in Amber C. King's work include Acute Lymphoblastic Leukemia research (10 papers), CAR-T cell therapy research (8 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Amber C. King is often cited by papers focused on Acute Lymphoblastic Leukemia research (10 papers), CAR-T cell therapy research (8 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Amber C. King collaborates with scholars based in United States, Germany and New Zealand. Amber C. King's co-authors include Martin S. Tallman, Troy Z. Horvat, Jae H. Park, F. R. Sanderson, Mark B. Geyer, Eytan M. Stein, Mikhail Roshal, Jacob L. Glass, Aaron D. Goldberg and Raajit K. Rampal and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Amber C. King

29 papers receiving 411 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amber C. King United States 11 204 157 117 108 105 31 419
Tomoo Osumi Japan 11 90 0.4× 110 0.7× 104 0.9× 35 0.3× 61 0.6× 54 374
C S Chen United States 7 246 1.2× 320 2.0× 32 0.3× 32 0.3× 141 1.3× 7 605
S. Murphy United States 8 121 0.6× 80 0.5× 49 0.4× 129 1.2× 65 0.6× 13 341
Brian Kwok United States 7 228 1.1× 205 1.3× 56 0.5× 120 1.1× 21 0.2× 15 516
Jamie Wilhelm United States 6 215 1.1× 162 1.0× 96 0.8× 85 0.8× 33 0.3× 13 369
Sylvia F. Pan United States 9 155 0.8× 135 0.9× 40 0.3× 105 1.0× 48 0.5× 18 416
Erin Guest United States 12 147 0.7× 353 2.2× 75 0.6× 30 0.3× 107 1.0× 34 551
Chunlin Zhou China 11 203 1.0× 253 1.6× 103 0.9× 61 0.6× 92 0.9× 69 461
Miori Inoue Japan 7 121 0.6× 241 1.5× 102 0.9× 33 0.3× 30 0.3× 10 365
Takahide Ara Japan 9 159 0.8× 69 0.4× 93 0.8× 37 0.3× 62 0.6× 54 324

Countries citing papers authored by Amber C. King

Since Specialization
Citations

This map shows the geographic impact of Amber C. King's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amber C. King with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amber C. King more than expected).

Fields of papers citing papers by Amber C. King

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amber C. King. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amber C. King. The network helps show where Amber C. King may publish in the future.

Co-authorship network of co-authors of Amber C. King

This figure shows the co-authorship network connecting the top 25 collaborators of Amber C. King. A scholar is included among the top collaborators of Amber C. King based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amber C. King. Amber C. King is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stahl, Maximilian, Kamal Menghrajani, Andriy Derkach, et al.. (2021). Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Advances. 5(5). 1552–1564. 108 indexed citations
2.
Glass, Jacob L., Andriy Derkach, Patrick Hilden, et al.. (2021). Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy. Leukemia Research. 106. 106569–106569. 3 indexed citations
3.
Rampal, Raajit K., Srđan Verstovšek, Sean M. Devlin, et al.. (2019). Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study. Blood. 134(Supplement_1). 4163–4163. 26 indexed citations
4.
King, Amber C., et al.. (2019). Cobimetinib‐induced “dropped head syndrome” and subsequent disease management in an Erdheim‐Chester patient. SHILAP Revista de lepidopterología. 7(10). 1989–1993. 7 indexed citations
5.
6.
King, Amber C., et al.. (2019). Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma. Journal of the Advanced Practitioner in Oncology. 10(8). 878–882. 19 indexed citations
7.
8.
Tremblay, Douglas, Amber C. King, Lihua Li, et al.. (2019). Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. Leukemia & lymphoma. 61(3). 660–667. 20 indexed citations
9.
10.
11.
Goldberg, Aaron D., Troy Z. Horvat, Meier Hsu, et al.. (2017). Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies. Blood. 130. 1353–1353. 18 indexed citations
12.
King, Amber C., et al.. (2017). Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies. Annals of Pharmacotherapy. 51(5). 410–416. 32 indexed citations
13.
Horvat, Troy Z., Larry W. Buie, Amber C. King, et al.. (2016). The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance. Leukemia Research. 50. 17–20. 16 indexed citations
14.
King, Amber C., et al.. (2015). Once daily versus twice daily enoxaparin for acute pulmonary embolism in cancer patients. Journal of Oncology Pharmacy Practice. 22(2). 265–270. 4 indexed citations
15.
Rathkopf, Dana E., Monica Fornier, Manish A. Shah, et al.. (2004). A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3072–3072. 6 indexed citations
16.
Berlin, Jordan, Amber C. King, Kendra D. Tutsch, et al.. (1994). A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma. Investigational New Drugs. 12(2). 137–141. 9 indexed citations
17.
King, Amber C., et al.. (1990). Aspects of eyespot control in wheat.. Zeitschrift für Pflanzenkrankheiten und Pflanzenschutz. 97(3). 237–349. 2 indexed citations
18.
Sanderson, F. R. & Amber C. King. (1988). Field Occurrence of Tapesia Yallundae, the Teleomorph of Pseudocercosporella Herpotrichoides.. Australasian Plant Pathology. 17(1). 20–20. 20 indexed citations
19.
King, Amber C., Anthony L. J. Cole, & F. R. Sanderson. (1986). Prochloraz Insensitivity in Isolates of the Cereal Eyespot Fungus, Pseudocercosporella Herpotrichoides, in New Zealand.. Australasian Plant Pathology. 15(1). 22–22. 7 indexed citations
20.
King, Amber C., P. R. SCOTT, M.G. Cromey, & F. R. Sanderson. (1984). Resistance to benomyl by eye-spot fungus on cereals in Southland. Proceedings of the New Zealand Weed Control Conference. 37. 290–293. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomoo Osumi Breakdown of academic impact, for papers by C S Chen Breakdown of academic impact, for papers by S. Murphy Breakdown of academic impact, for papers by Brian Kwok Breakdown of academic impact, for papers by Jamie Wilhelm Breakdown of academic impact, for papers by Sylvia F. Pan Breakdown of academic impact, for papers by Erin Guest Breakdown of academic impact, for papers by Chunlin Zhou Breakdown of academic impact, for papers by Miori Inoue Breakdown of academic impact, for papers by Takahide Ara
Rankless by CCL
2026